Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow-derived mesenchymal stem cells

Journal of Tissue Engineering and Regenerative Medicine

Volumn 3, Issue 3, 2009, Pages 163-174

  Pal, Rakhi ^a   Hanwate, Madhuri ^b   Jan, Majahar ^b   Totey, Satish ^a  

^a Manipal Academy of Higher Education   (India)

^b MANIPAL HOSPITAL   (India)

Author keywords

Bone marrow; Culture; Mesenchymal stem cells; Optimal medium; Reduced serum; Xeno free

Indexed keywords

BODY FLUIDS; BONE; CLINICAL RESEARCH; DISEASE CONTROL; FLOWCHARTING; GLUCOSE; STEM CELLS;

BONE MARROW; BONE MARROW-DERIVED MESENCHYMAL STEM CELLS; BONE-MARROW-DERIVED MESENCHYMAL STEM CELLS; CULTURE; CULTURE CONDITIONS; MESENCHYMAL STEM CELL; OPTIMAL MEDIUM; REDUCED SERUM; UPSCALING; XENO-FREE;

CELL CULTURE;

GLUCOSE; KNOCKOUT SERUM RELACEMENT; TISSUE CULTURE MEDIUM; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ARTICLE; BONE MARROW CELL; BOVINE SERUM; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; CULTURE TECHNIQUE; DULBECCO MODIFED EAGLE MEDIUM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MESENCHYME CELL; MESENCULT; PHENOTYPE; PLASMA; PRIORITY JOURNAL; ADIPOCYTE; ADULT; CELL CULTURE; CELL MEMBRANE; CELL SHAPE; COMPARATIVE STUDY; CYTOLOGY; KARYOTYPING; MALE; MESENCHYMAL STEM CELL; METABOLISM; METHODOLOGY; OSTEOBLAST; TIME;

ADIPOCYTES; ADULT; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL MEMBRANE; CELL SHAPE; CELLS, CULTURED; CULTURE MEDIA; FLOW CYTOMETRY; HUMANS; KARYOTYPING; MALE; MESENCHYMAL STEM CELLS; OSTEOBLASTS; PHENOTYPE; TIME FACTORS;

EID: 67649203411     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.143     Document Type: Article

References (18)

1. Aggarwal S, Pittenger MF. 2005; Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4): 1815-1822.
2. Bonab MM, Alimoghaddam K, Talebian F, et al. 2006; Aging of mesenchymal stem cell in vitro. BMC Cell Biol 7: 14.
3. Campagnoli C, Bellantuono I, Kumar S, et al. 2002; High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy. British Journal of Obstetrics and Gynaecology 109(8): 952-954.
4. Cízková D, Rosocha J, Vanický I, et al. 2006; Transplants of human mesenchymal stem cells improve functional recovery after spinal cord injury in the rat. Cell Mol Neurobiol 26(7-8): 1167-1180.
5. Deng YB, Liu XG, Liu ZG, et al. 2006; Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: evidence from a study in rhesus monkeys. Cytotherapy 8(3): 210-214.
6. Erices AA, Allers CI, Conget PA, et al. 2003; Human cord blood-derived mesenchymal stem cells home and survive in the marrow of immunodeficient mice after systemic infusion. Cell Transpl 12(6): 555-561.
7. Götherström C, Ringdén O, Westgren M, et al. 2003; Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant 32(3): 265-272.
8. Horwitz EM. 2006; MSC: a coming of age in regenerative medicine. Cytotherapy 8(3): 194-195.
9. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. 2004; Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 22(7): 1338-1345.
10. Le Blanc K. 2003; Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 5(6): 485-489 [review].
11. Meirelles Lda S, Nardi NB. 2003; Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol 123(4): 702-711.
12. Moviglia GA, Fernandez Viña R, Brizuela JA, et al. 2006; Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 8(3): 202-209.
13. Pittenger MF, Mackay AM, Beck SC, et al. 1999; Multilineage potential of adult human mesenchymal stem cells. Science 284(5411): 143-147.
14. Pittenger MF, Martin BJ. 2004; Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95(1): 9-20 [review].
15. Shahdadfar A, Frønsdal K, Haug T, et al. 2005; In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 23(9): 1357-1366.
16. Sotiropoulou PA, Perez SA, Salagianni M, et al. 2006; Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 24(2): 462-471.
17. Wollert KC, Drexler H. 2005; Mesenchymal stem cells formyocardial infarction: promises and pitfalls. Circulation 112(2): 151-153.
18. WuGD, Nolta JA, Jin YS, et al. 2003; Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 75(5): 679-685.